Mexico market update (2013)
Changes in the market
Two years ago the law changed in Mexico, meaning that today an international company can sell pharmaceutical products without having a plant (production line) in the country.
A lot of well known and small international companies are arriving in Mexico from Europe, India and China mainly. The generic market is booming in Mexico with many major players being local companies. They compete with price and a strong local sales force.
The current market
The government market is still very important for the pharmaceutical, medical devices and subscription markets (RX), but profits are low.
In Mexico, 15% of the population is at risk of having diabetes. Mexico has the highest number per capita in the world of consumers of carbonated drinks and is second after the US in revenue. Roche Diabetes has 59% of market share and is lobbying with the new president to try and get a subvention for patients, which will increase market activity.
Other recruitment firms (local and global) have healthcare and life sciences divisions, but PageGroup is the only one in this market focusing on technical positions.
In the last four years Roche, Novartis, Lilly, Abbott and Pfizer have all gone through restructures, so there’s been much hiring activity around this. The average period a candidate stays at one company is around two years and there are a lot of professional opportunities on the market because of the entrance of new organisations.
Michael Page Healthcare & Life Sciences works with medium sized international companies in Mexico and some local organisations, using direct search method to find the best talent.
If you’re looking for new opportunities or need top talent for your organisation, get in touch to find out more about our healthcare and life sciences recruitment in Mexico.